FDA Adverse Event Injury Summary report: N

ACRYSOF

MDR report key: 1230195 · Received November 13, 2008

Report

Report Number
1119421-2008-00901
Event Type
Injury
Date Received
November 13, 2008
Date of Event
December 1, 2005
Report Date
October 14, 2008
Manufacturer
ALCON RESEARCH, LTD./HUNTINGTON
Product Code
HQL
PMA / PMN Number
P930014
Removal / Correction Number
NA
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE PRODUCT WAS NOT RETURNED FOR ANALYSIS; THE DEVICE REMAINS IMPLANTED. PRODUCT HISTORY RECORDS COULD NOT BE REVIEWED BECAUSE THE REPORTING FACILITY DID NOT PROVIDE A LOT NUMBER OR ANY IDENTIFICATION TRACEABLE TO THE MANUFACTURING DOCUMENTATION. ADDITIONAL INFO HAS BEEN REQUESTED. BOUTBOUL S, LETAIEF I, LALLOUM F. PUECH M, BORDERIE V. LAROCHE L. (2008). PIGMENTARY GLAUCOMA SECONDARY TO IN-THE-BAG INTRAOCULAR LENS IMPLANTATION. J CATARACT REFRACT SURG. 2008 SEPT; 34: 1595-97. THIS REPORT WAS MAILED TO FDA ON: 11/13/2008.

Description of Event or Problem · 1

IN A JOURNAL ARTICLE, A SURGEON REPORTED HAVING A PT THAT DEVELOPED PIGMENTARY GLAUCOMA FOLLOWING IN-THE-BAG INTRAOCULAR LENS (IOL) IMPLANT SURGERY. FROM THE FOURTH DAY POSTOPERATIVELY, THE INTRAOCULAR PRESSURE (IOP) INCREASED AND WAS CONTROLLED WITH ANTIGLAUCOMA MEDICATIONS. THE VISUAL ACUITY REMAINED 20/20. TO CONTROL THE IOP, FILTERING SURGERY WAS PERFORMED IN 2006. AT THAT TIME, IT WAS ALSO DISCOVERED THAT THE POSTERIOR SURFACE OF THE IRIS WAS BEING RUBBED BY THE INFERIOR HAPTIC OF THE IOL, WHICH WAS IN THE BAG AND DEFORMED. THE HAPTIC WAS PUSHED DOWNWARD TO RESTORE IT TO ITS PROPER SHAPE. AFTER THE FILTERING SURGERY, THE PT'S VISUAL FUNCTION STABILIZED AND INTRAOCULAR PRESSURES REMAINED NORMAL WITHOUT MEDICATIONS. ADDITIONAL INFO HAS BEEN REQUESTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ACRYSOF INTRAOCULAR LENS HQL ALCON RESEARCH, LTD./HUNTINGTON SA60AT NI

Patients

Seq Age Sex Outcome Treatment
1 52 YR Required Intervention